Concepedia

Mark Whitaker

MW

5

Publications

300

Citations

5

H-Index

1979

Active since

Affiliations

Washington University in St. Louis(Current)

GlaxoSmithKline (United Kingdom)

GlaxoSmithKline (United States)

The Ohio State University

Research Triangle Park Foundation

Mark Whitaker is an author at Washington University in St. Louis specializing in medicine, pharmacology, and thrombosis.

ORCID

Top concepts

Publications per year

1979–2022

5

Publications

5

Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: Pharmacological basis for a therapeutic approach

Philip Needleman, Mark Whitaker, Angela Wyche et al. · Prostaglandins · 1980 · 130 citations

, , +9

Triene prostaglandins: Prostaglandin D <sub>3</sub> and icosapentaenoic acid as potential antithrombotic substances

Mark Whitaker, Angela Wyche, F.A. Fitzpatrick et al. · Proceedings of the National Academy of Sciences · 1979 · 123 citations · Full text

A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties

Neil Moss, Younggi Choi, Derek A. Cogan et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 25 citations · Full text

, , +8

Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772

Debra Tompson, Mark Whitaker, Rennan Pan et al. · Pharmaceutical Research · 2021 · 11 citations · Full text

Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology

Debra Tompson, Mark Whitaker, Rennan Pan et al. · Pharmaceutical Research · 2022 · 11 citations · Full text

Rows per page

1–5 of 5